Get the Stockscreener App
3.87
2.03%
-0.08
Athira Pharma Inc stock is traded at $3.87, with a volume of 17,973.
It is down -2.03% in the last 24 hours and down -17.66% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$3.95
Open:
$3.89
24h Volume:
17,973
Relative Volume:
0.32
Market Cap:
$15.26M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-1.2524
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-2.03%
1M Performance:
-17.66%
6M Performance:
+1,150%
1Y Performance:
+564.95%
1-Day Range:
$3.86
$4.132
1-Week Range:
$3.84
$4.34
52-Week Range:
$0.2195
$5.00
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
3.87 | 15.58M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Contrasting Day One Biopharmaceuticals (NASDAQ:DAWN) & Athira Pharma (NASDAQ:ATHA) - Defense World
Entry Recap: Will Athira Pharma Inc stock outperform growth indexesJuly 2025 Update & Free Risk Controlled Daily Trade Plans - moha.gov.vn
How Athira Pharma Inc. stock trades before earningsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Will Athira Pharma Inc. stock outperform growth indexes2025 Market Overview & Accurate Buy Signal Alerts - Newser
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
What analysts say about Athira Pharma Inc stockIndustrial Stocks Review & Start Learning With Our Courses - earlytimes.in
Why Athira Pharma Inc. stock could benefit from AI revolutionJuly 2025 Summary & High Yield Equity Trading Tips - newser.com
How Athira Pharma Inc. stock performs during Fed tightening cycles2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Athira Pharma Inc. stock outlook for YEARGap Up & Weekly Market Pulse Updates - newser.com
Why Athira Pharma Inc. stock is popular among millennialsEarnings Trend Report & Daily Oversold Stock Bounce Ideas - newser.com
How to escape a deep drawdown in Athira Pharma Inc.Earnings Growth Summary & Consistent Return Strategy Ideas - newser.com
What makes Athira Pharma Inc. stock attractive to growth fundsJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Will Athira Pharma Inc. stock benefit from AI adoption2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Top chart patterns to watch in Athira Pharma Inc.July 2025 EndofMonth & Real-Time Volume Triggers - newser.com
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC) - The Globe and Mail
What indicators show strength in Athira Pharma Inc.July 2025 Pullbacks & Capital Efficient Trade Techniques - newser.com
What analyst consensus says on Athira Pharma Inc. stock2025 Market Outlook & Capital Efficient Trade Techniques - newser.com
Will Athira Pharma Inc. continue its uptrendEarnings Growth Report & Real-Time Chart Breakout Alerts - newser.com
Update Recap: Is Athira Pharma Inc. stock ready for breakoutBull Run & Daily Chart Pattern Signal Reports - Fundação Cultural do Pará
ATHA | Athira Pharma Inc. SEC Filings - MarketWatch
Risk vs reward if holding onto Athira Pharma Inc.Quarterly Growth Report & Accurate Intraday Trading Signals - newser.com
Athira Pharma Inc. stock volume spike explainedWeekly Profit Report & Weekly Consistent Profit Watchlists - newser.com
Can Athira Pharma Inc. stock deliver consistent earnings growthDollar Strength & Long-Term Growth Portfolio Plans - newser.com
Real time alert setup for Athira Pharma Inc. performanceRate Cut & Consistent Return Strategy Ideas - newser.com
Is Athira Pharma Inc. stock cheap at current valuationJuly 2025 Review & Weekly Stock Performance Updates - newser.com
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Athira Pharma Inc Stock (ATHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):